- Home
- PULM vs ALGS Comparison
PULM vs ALGS Comparison
Compare PULM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- ALGS
- Stock Information
- Founded
- PULM 2003
- ALGS 2018
- Country
- PULM United States
- ALGS United States
- Employees
- PULM N/A
- ALGS N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- ALGS Health Care
- Exchange
- PULM Nasdaq
- ALGS Nasdaq
- Market Cap
- PULM 30.9M
- ALGS 32.4M
- IPO Year
- PULM N/A
- ALGS 2020
- Fundamental
- Price
- PULM $6.20
- ALGS $4.48
- Analyst Decision
- PULM
- ALGS Strong Buy
- Analyst Count
- PULM 0
- ALGS 1
- Target Price
- PULM N/A
- ALGS $70.00
- AVG Volume (30 Days)
- PULM 8.4K
- ALGS 134.4K
- Earning Date
- PULM 05-20-2025
- ALGS 05-06-2025
- Dividend Yield
- PULM N/A
- ALGS N/A
- EPS Growth
- PULM N/A
- ALGS N/A
- EPS
- PULM N/A
- ALGS N/A
- Revenue
- PULM $7,806,000.00
- ALGS $3,270,000.00
- Revenue This Year
- PULM N/A
- ALGS $580.86
- Revenue Next Year
- PULM $134.88
- ALGS N/A
- P/E Ratio
- PULM N/A
- ALGS N/A
- Revenue Growth
- PULM 6.96
- ALGS N/A
- 52 Week Low
- PULM $1.72
- ALGS $3.76
- 52 Week High
- PULM $10.40
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- PULM 46.38
- ALGS 35.72
- Support Level
- PULM $5.88
- ALGS $4.20
- Resistance Level
- PULM $6.85
- ALGS $6.35
- Average True Range (ATR)
- PULM 0.30
- ALGS 0.66
- MACD
- PULM 0.02
- ALGS 0.24
- Stochastic Oscillator
- PULM 30.93
- ALGS 13.02
About PULM Pulmatrix Inc.
Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.